1287 related articles for article (PubMed ID: 9068931)
1. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
Caccia S
Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of selective serotonin reuptake inhibitors.
Hiemke C; Härtter S
Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Baumann P; Rochat B
Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
[TBL] [Abstract][Full Text] [Related]
7. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
9. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
Hemeryck A; Belpaire FM
Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
[TBL] [Abstract][Full Text] [Related]
10. Care of depression in the elderly: comparative pharmacokinetics of SSRIs.
Baumann P
Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S35-43. PubMed ID: 9817619
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
12. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
Spina E; Santoro V; D'Arrigo C
Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982
[TBL] [Abstract][Full Text] [Related]
13. Are pharmacokinetic drug interactions with the SSRIs an issue?
Brøsen K
Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
van Harten J
Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
[TBL] [Abstract][Full Text] [Related]
15. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.
Lane RM
Int Clin Psychopharmacol; 1996 Dec; 11 Suppl 5():31-61. PubMed ID: 9032002
[TBL] [Abstract][Full Text] [Related]
17. Differences in interactions of SSRIs.
Brøsen K
Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S45-7. PubMed ID: 9817620
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
Luong TT; Powers CN; Reinhardt BJ; Weina PJ
Curr Res Pharmacol Drug Discov; 2022; 3():100112. PubMed ID: 35756846
[TBL] [Abstract][Full Text] [Related]
19. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
20. Overview of the pharmacokinetics of fluvoxamine.
van Harten J
Clin Pharmacokinet; 1995; 29 Suppl 1():1-9. PubMed ID: 8846617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
